A detailed history of Moore Capital Management, LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Moore Capital Management, LP holds 185,000 shares of RARE stock, worth $7.6 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
185,000
Previous 185,000 -0.0%
Holding current value
$7.6 Million
Previous $8.85 Million 2.36%
% of portfolio
0.14%
Previous 0.16%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $1.11 Million - $1.72 Million
35,000 Added 23.33%
185,000 $8.85 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $1.57 Million - $2.1 Million
45,000 Added 42.86%
150,000 $5.35 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $2.8 Million - $3.91 Million
75,000 Added 250.0%
105,000 $4.84 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $1.11 Million - $1.46 Million
30,000 New
30,000 $1.2 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.88B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Moore Capital Management, LP Portfolio

Follow Moore Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Moore Capital Management, LP with notifications on news.